Advertisement

Selective Perfusion of Chemotherapeutic Agents

  • Henri-Marcel Hoogewoud

Abstract

As most chemotherapeutic drugs have a steep dose-response curve, the rationale for hepatic arterial infusion is to achieve a higher concentration of drugs in neoplastic lesions and to lower the systemic drug levels. Essays with labeled fluorodeoxyuridine (FUDR) show that drug concentration in neoplastic tissue after injection in the hepatic artery is nearly 15 times higher than after injection in the portal vein [1]. This study clearly demonstrates the advantage of administering regional chemotherapy through the hepatic artery, because tumorous areas in the liver obtain most of their blood supply from branches of the liver arteries whereas normal liver parenchyma is mainly supplied by the portal vein.

Keywords

Hepatocellular Carcinoma Liver Metastasis Hepatic Artery Sclerosing Cholangitis Celiac Trunk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sigurdson ER, Ridge JA, Kemeny N, Daly JM (1987) Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5: 1836–1840PubMedGoogle Scholar
  2. 2.
    Collins JM (1984) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498–504PubMedGoogle Scholar
  3. 3.
    Collins JM (1986) Pharmacologic rationale for hepatic arterial therapy. In: Herfarth C, Schlag P, Hohenberger P (eds) Therapeutic strategies in primary and metastatic liver cancer. Springer, Berlin Heidelberg New York, pp 140–148. (Recent results in cancer research, vol 100)CrossRefGoogle Scholar
  4. 4.
    Collins JM (1986) Pharmacologie rationale for hepatic arterial therapy. In Herfarth C, Schlag P, Hohenberger P (eds) Therapeutic strategies in primary and metastatic liver cancer. Springer, Berlin Heidelberg New York, p 143 (Recent results in cancer Research vol 100)Google Scholar
  5. 5.
    Michels NA (1955) Blood supply and anatomy of the upper abdominal organs. Lippincott, Philadelphia, pp 152–154, 256-259, 374-375Google Scholar
  6. 6.
    Cho KJ, Andrews JC, Williams DM, Doenz F, Guy GE (1989) Hepatic arterial chemotherapy: role of angiography. Radiology 173: 783–791PubMedGoogle Scholar
  7. 7.
    Chuang VP, Wallace S (1980) Hepatic arterial redistribution for intraarterial infusion of hepatic neoplasms. Radiology 135: 295–299PubMedGoogle Scholar
  8. 8.
    Sone Y, Arai Y, Tohyama N, Kido C (1991) Effect of posture for drug distribution in hepatic arterial infusion chemotherapy. 5th International Conference on Advances in Regional Cancer Treatment, June 17–19, RosenheimGoogle Scholar
  9. 9.
    Miller DL, Carrasquillo JA, Lutz RJ, Chang AE (1989) Hepatic perfusion during hepatic artery infusion chemotherapy: evaluation with perfusion CT and perfusion scintigraphy. J Comput Assist Tomogr 13(6): 958–964PubMedCrossRefGoogle Scholar
  10. 10.
    Andrews JC, Williams DM, Shapiro B, Ensminger WD (1989) Low infusion rate digital subtraction angiography to predict regional perfusion in hepatic arterial chemotherapy. Cardiovasc Intervent Radiol 12(5): 277–280PubMedCrossRefGoogle Scholar
  11. 11.
    Lefor AT, Hughes KS, Shiloni E, Steinberg SM, Vetto JT, Papa MZ, Sugarbaker PH, Chang AE (1988) Intra-abdominal extrahepatic disease in patients with colorectal hepatic metastases. Dis Colon Rectum 31: 100–103PubMedCrossRefGoogle Scholar
  12. 12.
    Pettavel J (1988) Intra-arterial chemotherapy using a pump. Antibiot Chemother 40: 36–40PubMedGoogle Scholar
  13. 13.
    Aeberhard P (1988) Intra-arterial chemotherapy without pump. Antibio Chemother 40: 41–50Google Scholar
  14. 14.
    Martin JK Jr, O’Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK, Krook JE (1990) Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125: 1022–1027PubMedCrossRefGoogle Scholar
  15. 15.
    Daly JM, Kemeny N, Sigurdson E, Oderman P, Thorn A (1987) Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. Arch Surg 122: 1273–1277PubMedCrossRefGoogle Scholar
  16. 16.
    Fisher ER, Turnbull TR (1955) The cytological demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal cancer. Surg Gynecol Obstet 100: 102–106PubMedGoogle Scholar
  17. 17.
    Wiggers T, Jeekel J, Arends JW, Brinkhorst AP, Kluck HM et al. (1988) No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg 75: 409–415PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor I, Rowling JT, West C (1979) Adjuvant cytotoxic liver perfusion for colorectal cancer. Br J Surg 66: 833–837PubMedCrossRefGoogle Scholar
  19. 19.
    Beart RW Jr, Moertel CG, Wieand HS, Leigh JE, Windschitl HE, van Heerden JA, Fitzgibbons RJ Jr, Wolff BG (1990) Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 125(7): 897–901PubMedCrossRefGoogle Scholar
  20. 20.
    Metzger U, Laffer U, Aeberhard P, Arigoni M, Arma S, Barras J, Egli R, Martinoli S, Mueller W, Schweizer W (1990) Randomized multicenter trial of adjuvant intraportal chemotherapy for colorectal cancer SAKK 40/81: an interim report. Acta Chir Scand 156: 467–474PubMedGoogle Scholar
  21. 21.
    Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL (1990) Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 65(3): 425–432PubMedCrossRefGoogle Scholar
  22. 22.
    O’Connell MJ (1990) Is portal-vein fluorouracil hepatic infusion effective colon cancer surgical adjuvant therapy? (Editorial) J Clin Oncol 8: 1454–1456PubMedGoogle Scholar
  23. 23.
    Metzger U (1990) Adjuvante Therapie des Kolonkarzinoms. Schweiz Med Wochenschr 120: 1149–1158PubMedGoogle Scholar
  24. 24.
    Moertel CG, Fleming TR, Mcdonald JS, Haller DG, Lautie JA et al. (1990) Levamisole and fluorouracil for adjuvant chemotherapy of resected carcinoma. N Engl J Med 322: 352–358PubMedCrossRefGoogle Scholar
  25. 25.
    Cunliffe WJ, Sugarbaker PH (1989) Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 76: 1082–1090PubMedCrossRefGoogle Scholar
  26. 26.
    Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE (1985) Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98: 414–422PubMedGoogle Scholar
  27. 27.
    August DA, Sugarbaker PH, Ottow RT, Ottow FJ, Schneider PD (1985) Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg 201: 210–218PubMedCrossRefGoogle Scholar
  28. 28.
    Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P (1990) Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 50: 5790–5794PubMedGoogle Scholar
  29. 29.
    Mavligit GM, Zukiwski AA, Charnsangavej C, Carrasco CH, Wallace S, Gutterman JU (1992) Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer 69: 557–561PubMedCrossRefGoogle Scholar
  30. 30.
    Park C, Choi SI, Kim H, Yoo HS, Lee YB (1990) Distribution of Lipiodol in hepatocellular carcinoma. Liver 10(2): 72–78PubMedGoogle Scholar
  31. 31.
    Katagiri Y, Mabuchi K, Itakura T, Naora K, Iwamoto K, Nozu Y, Hirai S, Ikeda N, Kawai T (1989) Adriamycin-Lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma. Cancer Chemother Pharmacol 23(4): 238–242PubMedCrossRefGoogle Scholar
  32. 32.
    Okazaki M, Higashihara H, Koganemaru F, Nakamura T, Kitsuki H, Hoaschi T, Makuuchi M (1991) Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization. Radiology 180: 647–651PubMedGoogle Scholar
  33. 33.
    Audisio RA, Doci R, Mazzaferro V, Bellegotti L, Tommasini M, Montalto F, Marchiano A, Piva A, DeFazio C, Damascelli B et al. (1990) Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. Cancer 66(2): 228–236PubMedCrossRefGoogle Scholar
  34. 34.
    Mantravadi RVP, Spigos DG, Tan WS, Felix EL (1982) Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 142: 783–786PubMedGoogle Scholar
  35. 35.
    Nakao N, Ishikura R, Miura K, Takahashi H, Miura T (1987) Transcatheter arterial embolization in hepatoma complicated with obstructive jaundice. Cardiovasc Intervent Radiol 10: 40–42PubMedCrossRefGoogle Scholar
  36. 36.
    Shibata T, Sasaki Y, Imaoka S, Nagano H, Iwanaga T, Fujita M, Ishiguro S (1990) Evaluation of preoperative chemoembolization using ethiodized oil, cisplatin and gelatin sponge (sandwich therapy) for hepatocellular carcinoma. Nippon Geka Gakkai Zasshi 91(7): 859–863PubMedGoogle Scholar
  37. 37.
    Fujio N, Sakai K, Kinoshita H, Hirohashi K, Kubo S, Iwasa R, Lee KC (1989) Results of treatment of patients with hepatocellular carcinoma with severe cirrhosis of the liver. World J Surg 13(2): 211–217PubMedCrossRefGoogle Scholar
  38. 38.
    Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H et al. (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60(6): 1194–1203PubMedCrossRefGoogle Scholar
  39. 39.
    Castrucci M, Sironi S, Vanzulli A, Angeli E, Venturini M, Mellone R, Taccagni G, Cantaboni A, Marenghi C, Ferrari G et al. (1990) Valutazione istologica postoperatoria dell’epatocarcinoma trattato mediante chemioembolizzazione. Radiol Med (Torino) 80(1-2): 79–84Google Scholar
  40. 40.
    Nagasue N, Galizia G, Kohno H, Chang YC, Hayashi T, Yamanoi A, Nakamura T, Yukaya H (1989) Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 106(1): 81–86PubMedGoogle Scholar
  41. 41.
    Hwang TL, Chen MF, Lee TY, Chen TJ, Lin DY, Liaw YF (1987) Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization. Arch Surg 122: 756–759PubMedCrossRefGoogle Scholar
  42. 42.
    Falkson G, Cnaan A, Schutt AJ, Ryan LM, Falkson HC (1988) TI prognostic factors for survival in hepatocellular carcinoma. Cancer Res 48: 7314–7318PubMedGoogle Scholar
  43. 43.
    Attali P, Prod’Homme S, Pelletier G et al. (1987) Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 59: 2108–2111PubMedCrossRefGoogle Scholar
  44. 44.
    Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918–928PubMedCrossRefGoogle Scholar
  45. 45.
    Sato Y, Fujiwara K, Ogata I, Ohta Y, Hayashi S, Oka Y, Furui S, Oka H (1985) Transcatheter arterial embolization for hepatocellular carcinoma. Benefits and limitations for unresectable cases with liver cirrhosis evaluated by comparison with other conservative treatments. Cancer 55: 2822–2825PubMedCrossRefGoogle Scholar
  46. 46.
    Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11: 181–184PubMedCrossRefGoogle Scholar
  47. 47.
    Ohnishi K, Tanabe Y, Ryu M, Isono K, Yamamoto Y, Usui S, Hiyama Y, Goto N, Iwama S, Sugita S et al. (1987) Prognosis of hepatocellular carcinoma smaller than 5 cm in relation to treatment: study of 100 patients. Hepatology 7: 1285–1290PubMedCrossRefGoogle Scholar
  48. 48.
    Musset D, Gorce F, Roche A (1985) Embolisation des métastases hépatiques. Ann Gastroenterol Hepatol (Paris) 162: 849–859Google Scholar
  49. 49.
    Roche A, Franco D, Dhumeaux D, Bismuth H (1979) Emergency hepatic arterial embolization for secondary hypercalcemia in hepatocellular carcinoma. Radiology 133: 315–316PubMedGoogle Scholar
  50. 50.
    Sato Y, Fujiwara K, Furui S, Ogata I, Oka Y, Hayashi S, Ohta Y, Iio M, Oka H (1985) Benefit of transcatheter arterial embolization for ruptured hepatocellular carcinoma complicating liver cirrhosis. Gastroenterology 89: 157–159PubMedGoogle Scholar
  51. 51.
    Nouchi T, Nishimura M, Maeda M, Funatsu T, Hasumura Y, Takeuchi J (1984) Transcatheter arterial embolization of ruptured hepatocellular carcinoma associated with liver cirrhosis. Dig Dis Sci 29: 1137–1141PubMedCrossRefGoogle Scholar
  52. 52.
    Hsu HC, Wei TC, Tsang YM, Wu MZ, Lin YH, Chuang SM (1986) Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization. Cancer 57: 1184–1191PubMedCrossRefGoogle Scholar
  53. 53.
    Sitzman JV, Order SE, Klein JL et al. (1987) Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5: 1566Google Scholar
  54. 54.
    Roche A (1991) Indication, contre-indications, résultats des chimio-embolisations. Les questions du chirurgien, les réponses du radiologue en pathologie hépatique et pancréatique. 45èmes Journées du service de Radiologie, Hôpital St-AntoineGoogle Scholar
  55. 55.
    Miyayama S, Matsui O, Kameyama T, Hirose J, Konishi H, Chyotoh S, Kadoya M, Takashima T (1990) Angiographie anatomy of arterial branches to the caudate lobe of the liver with special reference to its effect on transarterial embolization of hepatocellular carcinoma. Rinsho Hoshasen 35(3): 353–359PubMedGoogle Scholar
  56. 56.
    Wakasa K, Sakurai M, Kuroda C, Marukawa T, Monden M, Okamura J, Kurata A (1990) Effect of transcatheter arterial embolization on the boundary architecture of hepatocellular carcinoma. Cancer 65: 913–919PubMedCrossRefGoogle Scholar
  57. 57.
    Kato T, Niwa M, Saito Y, Ogoshi K, Shimizu K, Nashimoto A, Kato K, Akai S (1990) Evaluation of quality of life in arterial infusion chemotherapy of hepatocellular carcinoma. Gan To Kagaku Ryoho 17(8 Pt 2): 1623–1628PubMedGoogle Scholar
  58. 58.
    Marlink RG, Lokich JJ, Robins JR, Clouse ME (1990) Hepatic arterial embolization for metastatic hormone-secreting tumors. Technique, effectiveness, and complications. Cancer 65(10): 2227–2232PubMedCrossRefGoogle Scholar
  59. 59.
    Odurny A, Birch SJ (1985) Hepatic arterial embolisation in patients with metastatic carcinoid tumours. Clin Radiol 36: 597–602PubMedCrossRefGoogle Scholar
  60. 60.
    Stockmann F, von Romatowski HJ, Reimold WV, Schuster R, Creutzfeldt W (1984) Hepatic artery embolization for treatment of endocrine gastrointestinal tumors with liver metastases. Z Gastroenterol 22: 652–660PubMedGoogle Scholar
  61. 61.
    Sasaki Y, Imaoka S, Masutani S, Nagano H, Ohashi I, Kameyama M, Fukuda I, Ishikawa O, Ohigashi H, Hiratsuka M et al. (1990) Chemoembolization for liver metastasis from colorectal cancer. Gan To Kagaku Ryoho 17(8): 1661–1664PubMedGoogle Scholar
  62. 62.
    Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, Sato N, Nakashima K, Urata J, Yoshizumi K et al. (1990) Prognostic factors in liver metastases after transcatheter arterial embolization or arterial infusion. Acta Radiol 31(3): 269–274PubMedGoogle Scholar
  63. 63.
    Inoue H, Kobayashi H, Itoh Y, Shinohara S (1989) Treatment of liver metastases by arterial injection of Adriamycin/mitomycin C lipiodol suspension. Acta Radiol 30: 603–608PubMedCrossRefGoogle Scholar
  64. 64.
    Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC (1990) Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8(6): 1108–1114PubMedGoogle Scholar
  65. 65.
    Allison DJ, Jordan H, Hennessy O (1985) Therapeutic embolisation of the hepatic artery: a review of 75 procedures. Lancet 1(8429): 595–599PubMedCrossRefGoogle Scholar
  66. 66.
    Herrmann G, Lorenz M, Kirkowa-Reimann M, Hottenrott C, Hubner K (1987) Morphological changes after intra-arterial chemotherapy of the liver. Hepatogastroenterology 34(1): 5–9PubMedGoogle Scholar
  67. 67.
    Ludwig J, Kim CH, Wiesner RH, Krom RA (1989) Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 9(2): 215–218PubMedCrossRefGoogle Scholar
  68. 68.
    Fukuzumi S, Moriya Y, Makuuchi M, Terui S (1990) Serious chemical sclerosing cholangitis associated with hepatic arterial 5FU and MMC chemotherapy. Eur J Surg Oncol 16(3): 251–255PubMedGoogle Scholar
  69. 69.
    Chuang VP, Wallace S, Stroehlein J, Yap HY, Patt YZ (1981) Hepatic artery infusion chemotherapy: gastroduodenal complications. AJR Am J Roentgenol 137: 347–350PubMedGoogle Scholar
  70. 70.
    Takayasu K, Moriyama N, Muramatsu Y, Shima Y, Ushio K, Yamada T, Kishi K, Hasegawa H (1985) Gallbladder infarction after hepatic artery embolization. AJR Am J Roentgenol 144: 135–138PubMedGoogle Scholar
  71. 71.
    Jeng KS, Chiang HJ (1989) Delayed formation of gallstone after transcatheter arterial embolization for hepatocellular carcinoma. Is elective cholecystectomy advisable during hepatectomy? Arch Surg 124(11): P1319–P1322CrossRefGoogle Scholar
  72. 72.
    Moran KT, Halpin DP, Zide RS, Oberfield RA, Jewell ER (1988) Long-term brachial artery catheterization: ischemic complications. J Vasc Surg 8(1): 76–78PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Henri-Marcel Hoogewoud
    • 1
  1. 1.Cantonal HospitalFribourgSwitzerland

Personalised recommendations